Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment-Reference-Cited by-同舟云学术

Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment

Published:2021-04-01 Issue: Volume: Page:1-6
ISSN:0927-3948
Container-title:Ocular Immunology and Inflammation
language:en
Short-container-title:Ocular Immunology and Inflammation

Author:

Bolletta Elena¹,Gozzi Fabrizio¹,Mastrofilippo Valentina¹,Pipitone Nicolò²,De Simone Luca¹,Croci Stefania³,Invernizzi Alessandro⁴^ORCID,Adani Chantal¹^ORCID,Iannetta Danilo⁵,Coassin Marco⁶,Fontana Luigi⁵,Salvarani Carlo²⁷^ORCID,Cimino Luca¹^ORCID

Affiliation:

1. Ocular Immunology Unit, Azienda USL-IRCCS, Reggio Emilia, Italy

2. Rheumatology Unit, Azienda USL-IRCCS, Reggio Emilia, Italy

3. Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS, Reggio Emilia, Italy

4. Eye Clinic, Department of Biomedical and Clinical Science “L. Sacco”, Luigi Sacco Hospital, University of Milan, Milan, Italy

5. Ophthalmology Unit, Azienda USL-IRCCS, Reggio Emilia, Italy

6. Department of Ophthalmology, University Campus Bio-Medico of Rome, Rome, Italy

7. Department of Surgery, Medicine, Dentistry and Morphological Sciences, with Interest in Transplants, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy

Publisher

Informa UK Limited

Subject

Ophthalmology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/09273948.2021.1880604

Reference33 articles.

1. Vogt-Koyanagi-Harada syndrome

2. Catching the therapeutic window of opportunity in early initial-onset Vogt–Koyanagi–Harada uveitis can cure the disease

3. Immunomodulatory Therapy for Vogt-Koyanagi-Harada Patients as First-Line Therapy

4. Reappraisal of the management of Vogt–Koyanagi–Harada disease: sunset glow fundus is no more a fatality

5. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vogt-Koyanagi-Harada Disease;Ocular Immunology and Inflammation;2024-04-20

2. Progress in the Use of Glucocorticoids and Biological Agents in Non-Infectious Uveitis;Journal of Biosciences and Medicines;2024

3. Comprehensive and updated review on the diagnosis and treatment of Vogt-Koyanagi-Harada disease;Annals of Eye Science;2023-06

4. Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature;Journal of Ophthalmic Inflammation and Infection;2023-05-19

5. Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review;Pharmaceutics;2023-02-25